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INTRODUCTION 
The goal of treating ureteral calculi is to achieve complete 
stone clearance with minimal morbidity for the patient. The factors 
that  must be considered when recommending treatment to patients 
with ureteric calculi may be grouped into three broad categories: 
stone-related factors (location, size, composition, duration, and 
degree of obstruction), clinical factors (the patient's tolerance of 
symptomatic events, the patient's expectation, associated infection, 
solitary kidney, abnormal ureteric  anatomy, and technical factors 
(equipment available for treatment, costs). These factors may be 
thought of as treatment modifiers. Nevertheless, several surgical 
options are available for proximal ureteral calculi.  
Advances in ureteroscope design, newer methods of 
intracorporeal stone fragmentation, laparoscopic techniques and 
ongoing developments in extracorporeal shock wave lithotripsy have 
resulted in changes with regard to the use of treatment modalities for 
ureteral stones.1   
Extracorporeal shock wave lithotripsy (ESWL) is the least 
invasive treatment for calculi of the upper urinary tract and it is 
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recommended as first line therapy.2 However, ESWL has a variable 
success rate for large upper ureteral calculi.3,4 
Development of the small flexible ureterorenoscope combined 
with advancements in intracorporeal lithotriptors have increased the 
success rate for managing upper ureteral  calculi. However, flexible 
ureteroscopes are expensive and technique dependent. Moreover, the 
current trend in surgery is toward minimally invasive procedures. 
The use of stents for extracorporeal shock wave lithotripsy in 
certain renal  and ureteral stones remains controversial. The major 
benefit of stents is to prevent complications associated with ureteral 
obstruction as stone fragments pass down the ureter. Conversely, the 
main drawbacks associated with stents are irritative symptoms and 
bladder discomfort in addition to inherent risks of stent migration, 
vesicoureteral reflux and stent encrustation.5 
The effect of ureteric stent on the outcome of ESWL continues 
to pose a dilemma, with no clear published recommendations. 
Though the use of stents is unavoidable in some cases (e.g. 
obstruction, sepsis), ureteric stents have not always previously been 
identified as a factor associated with failure of ESWL, and some 
authors have claimed that it does not affect the treatment outcome.6,7 
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Success of ESWL has been correlated with radio density of the 
stone on the plain X-ray KUB.  Overall accuracy of predicting 
calculi composition from plain radiographs was reported to be only 
39% which at present is insufficient for clinical use. 
The emergence of Non Contrast Computed Tomography scan 
(NCCT) in the assessment of flank pain and the subsequent 
availability of the attenuation coefficient measurement has made 
several authors comparing attenuation and stone composition in 
vitro.  These studies have determined that stone compositions can be 
predicted on the basis of the attenuation value determined by NCCT. 
The density of stone measured by NCCT, stone Hounsfield 
Unit (HU) varies with stone composition and determines the fragility 
of a calculus which ultimately governs the clinical outcome in 
ESWL. NCCT because of its easy availability, excellent sensitivity 
and very high resolution capability is a good modality for the 
measurement of stone density. 
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AIM  
The aim of this study is  
1) To identify the effect of the presence of a ureteric stent on the 
outcome of extracorporeal shockwave lithotripsy (ESWL), by 
comparing patients with ureteric stones with matched-pair 
analysis. 
2) To find out complications of extracorporeal shock wave 
lithotripsy during the management of upper ureteric calculus 
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REVIEW OF LITERATURE 
THE EVOLUTION OF MACHINE DESIGN 
Shock wave lithotripsy (SWL) was introduced in the 1980s for 
the treatment of urinary stones and earned near-instantaneous 
acceptance as a first line treatment option. 
The word Lithotripter is Greek origin and means stone crusher. 
Lithotripters have evolved from many years of research into physics 
of flight. Researchers discovered that raindrops striking an air craft 
during supersonic flight created shockwaves that had disintegrating 
effects on solid materials. Refinements of these findings led to the 
invention of the Lithotripter as a means for treating urinary calculi.
 In February 1980 Dr.Christian Chaussay, at the University of 
Munich first used electrically generated focused shockwaves to 
fragment stones within a human kidney.8 The first experimental 
treatment began the era of ESWL. The first Lithotripter model HM 1 
soon replaced by HM 2 in 1982 and in 1984 by Model HM 3. Each 
new generation reflects progression of technology and a growing 
sophistication. Further modification of the generation is the 
consolidation of fluoroscopic screens and the lithotripsy control into 
a convenient, efficient and user friendly console. 
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Shockwave lithotripsy technology has advanced rapidly in 
terms of shock wave generation, focusing, patient coupling and stone 
localization making it the most widely used treatment for renal and 
ureteric calculi. Over the years, lithotripsy has undergone several 
waves of technological advancement, but with little change in the 
fundamentals of shock wave generation and delivery. 
Traditionally lithotriptors have been categorized as first-, 
second- or third generation (an unfortunate and confusing 
classification system) devices. The Dornier HM3 is the first 
generation lithotriptor. It features an electro hydraulic source 
mounted at the floor of a large water bath in which the patient is 
placed, and which provides for optimal coupling to deliver SW 
energy to the body. Stone localization is via biplanar fluoroscopic 
imaging. Depending upon the case at hand, local sedation, regional, 
or general anesthesia is applied. Second generation lithotriptors 
feature an electrohydraulic, electromagnetic or piezoelectric shock 
wave source (see below). Coupling is provided by a water cushion or 
partial water bath. The machines are further equipped with either 
ultrasonic or fluoroscopic imaging and have lessened anesthesia 
requirements. Limited multifunctional and/or multidisciplinary use is 
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possible. These devices generate peak pressures similar to or lower 
than the HM3 but with smaller focal zones. 
Third generation lithotriptors are equipped with a combined 
targeting system consisting of fluoroscopy and ultrasound to be used 
alternately or, in the ideal situation, simultaneously. They also have 
lessened anesthesia requirements and the integration of both 
fluoroscopy and ultrasound in an endourologic treatment table 
facilitate multi-functional and multidisciplinary use. These devices 
typically have higher peak pressures and smaller focal zones than the 
HM3. 
THE PHYSICS OF CLINICAL LITHOTRIPSY 
Three shock wave generating principles have been used in 
clinical lithotriptors.. 
a) Electrohydraulic lithotriptors (EHL-SWLs) 
An electrohydraulic shock wave source consists of a spark 
plug placed underwater with a gap of approximately 1 mm between 
the two electrode tips. A capacitor is charged to a voltage between 
12 and 30 kV and then abruptly discharged causing the explosive 
formation of an underwater plasma channel in the gap. The resulting 
rapid evaporation of the water surrounding the electrode tips releases 
a spherical (unfocused) shock wave. The spark plug is positioned at 
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the first focus (F1) of an ellipsoidal bowl and the spherical shock 
wave reflects from the surface of the ellipsoidal bowl and converges 
(focuses) at the second focus (F2).9  
 
Fig. 1.   Electrohydraulic lithotriptor 
The process causes erosion of the electrode tips leading to 
irregularities in the resulting spark and the shock wave originating 
from it. The erosion of the electrode tips thus limits the lifetime of 
the spark plug to several thousand shocks per spark plug. The 
Dornier HM3 had a complete water bath, which provided optimal 
coupling but subsequent EHL-SWLs have the shock wave source 
mounted in a sealed therapy head which is coupled to the body using 
gel or oil. 
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b) Electromagnetic lithotriptors (EMLs) 
Electromagnetic shock wave generators are available in several 
geometries. In one case an electric coil is formed on a flat surface 
and a conductive membrane placed on top. A capacitor is then 
discharged through the coil which produces a magnetic field that 
repels the membrane resulting in the generation of a plane 
(unfocused wave) which is focused with an acoustic lens. In another 
geometry the coil is wrapped around a cylinder (about the size of a 
soup can) and the wave spreads out cylindrically (unfocused) from 
the coil. 
 
Fig. 2.  Focusing mechanisms employed in electromagnetic 
lithotriptors A,  Focused by an acoustic lens. B, Focused by a 
parabolic reflector 
 10
The coil is placed within a parabolic reflector which acts to 
focus the cylindrical wave. In a third approach the coil is formed on 
the inner surface of a spherical cap. When the coil is excited the 
wave generated has the same curvature as the spherical cap and 
therefore starts off as a focused wave propagating toward the centre 
of the radius of curvature of the spherical surface.10 In all cases the 
initial wave is not a true shock wave but as it propagates towards the 
focus it evolves into a shock wave.  
All electromagnetic shock wave sources are in a sealed therapy 
head, which is coupled to the body using gel or oil, except for the 
Storz devices which couple the sealed therapy head via a small, 
shallow water bath. Electromagnetic shock wave sources are more 
consistent and reproducible than EHLSWL spark-gap sources and 
have a lifetime of about two million SW’s. 
c) Piezoelectric lithotriptors (PELs) 
A piezoelectric shockwave generator consists of a concave 
spherical cap lined on the inner surface with piezoceramic 
elements—typically hundreds or thousands are employed. 
Piezoceramic elements rapidly change shape in response to an 
electric current.  
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A capacitor is discharged through these elements, which 
because of the geometry of the sphere, produces an acoustic wave 
with a spherically converging wave front. The pressure wave focuses 
at the centre of the sphere. As with the EMLs the wave does not start 
as a shock wave but rather develops into a shock wave due to non-
linear propagation 
 
Fig. 3: (A) Fundamental principles for a piezoelectric lithotriptor.   
(B) Typical waveform measured at the focus of a piezoelectric 
lithotriptor 
Typically PELs are mounted in the therapy head like other SW 
sources. One notable exception was the original Wolf Piezolith 
which was equipped with a partial water bath bringing the patient in 
direct contact with the water. Although piezoelectric shockwave 
sources develop high focal pressures this technology generally is 
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considered to be less effective than other devices, as the clinical data 
shows a high re-treatment rate.11 
ASSESSMENT OF LITHOTRIPTOR PERFORMANCE 
Owing to the wide variety of makes and models of 
lithotriptors, with different generators and energies, and subtle 
variations in overall patient care among investigators, it becomes 
difficult to make comparisons between series of reported data. For 
example, for a given stone-free rate, one machine may require 
multiple re-treatments or subsequent stent placements. Denstedt and 
colleagues 12 described the use of an “efficiency quotient” to take 
such factors into account as follows: efficiency quotient (EQ) = % 
stone-free divided by (100 + % re-treated + % auxiliary procedures). 
Therefore, a lithotriptor with an 85% stone-free rate, 10% re-
treatment rate, and 15% rate of additional procedures would have an 
efficiency quotient of 0.68, whereas another machine which also has 
an 85% stone-free rate but with no re-treatments or ancillary 
procedures would have an EQ of 0.85. It is evident that despite the 
same stone-free rates, the two machines are not equally “efficient.” 
 This methodology is also useful in comparing results of SWL 
to other modalities, such as ureteroscopy or percutaneous 
nephrolithotomy. Unfortunately, only a small fraction of the current 
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peer-reviewed literature reported EQs, and stone-free rates were the 
primary measure of success. Overall results of SWL for solitary 
nonstaghorn renal calculi in any location vary from EQs of 0.45 to 
0.82 for electrohydraulic lithotriptors and 0.42–0.67 for 
electromagnetic lithotriptors.13,14 
SHOCK WAVE COUPLING 
Shock waves can be coupled effectively into body by degassed 
water which has matched acoustic impedance to soft tissues. Current 
Lithotripter use enclosed water cushion with a coupling medium of 
ultrasound gel instead of 1000 L water bath. Shock wave attenuation 
through the membrane of water cushion amounts to 20% loss of 
energy. 
STONE LOCALIZATION 
Stone localization during lithotripsy is accomplished with 
either fluoroscopy (or) ultrasonography.  
FLUOROSCOPY   
Advantages 
 In situ treatment of ureteral stones in all parts of the ureter 
 Shorter learning curve 
 Automatic positioning mode available on some systems 
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Disadvantages 
 No direct targeting of radiolucent stones 
 Small stones sometimes difficult to locate 
 No real-time image 
 Exposure to radiation 
ULTRASOUND 
Advantages 
 Easy targeting of radiolucent stones 
 Easier targeting of smaller renal stones 
 Real-time image: easier, faster focusing 
 No exposure to radiation 
Disadvantages 
 In situ treatment of ureteral stones is possible only for very 
proximal and very distal ureteral calculi 
 Longer learning curve 
 Poor imaging with obese patients 
PHYSICAL PROPERTIES OF CALCULI AND TISSUE 
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Knowledge of acoustic and mechanical properties of renal, 
ureteric calculi and tissue is important to understand shockwave – 
stone tissue interaction and the mechanisms of stone fragmentation 
and tissue injury during ESWL. Acoustic properties determine the 
characteristics of shock wave propagation inside the stone and tissue 
materials as well as the wave transmission and reflection, at the 
stone tissue boundary. Mechanical properties dictate the response of 
the stone and tissue materials to shock wave loadings. Acoustic and 
mechanical properties of calculi depend primarily on the 
composition of stone. 
Acoustic properties are density, wave speed and acoustic 
impedance. Longitudinal wave propagation (compression) 
characterized by parallel movements of material particles along the 
wave path. Transverse (Shear) wave propagation material particles 
move perpendicularly to wave path.  
Calcium oxalate monohydrate and cystine stones have higher 
acoustic impedance. Stones with higher acoustic impedance would 
produce a stronger reflection of the shock wave at the anterior 
surface of stone resulting in less of the shock wave energy being 
transmitted into the stone to cause fragmentation. 
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COMPOSITION AND STRUCTURAL FEATURES OF 
CALCULI 
The constituents of renal calculi are crystalline (95%) and non 
crystalline matrix materials (protein, cellular debris and organic 
materials).Major crystalline components are calcium oxalate 
(monohydrate and dihydrate), phosphates (hydroxyapatite, carbonate 
apatite - struvite) uric acid, cystine and xanthine. Calculi appear in 
wide range of shapes, sizes, colors and textures.  
MECHANICAL PROPERTIES OF CALCULI 
Dynamic elastic properties of calculi depends upon resistance 
of stone material to elongation (or) shortening, shear deformation 
and volume change. Most renal calculi are brittle while cystine 
stones are ductile (more energy is needed to produce fracture) so 
they are most difficult to fragment during SWL. 
MECHANISMS OF VARYING STONE FRAGILITY 
Stone fragility determines the response of a ureteric calculus to 
SWL. The response varies with composition, size and structural 
features of stone. 
It has been reported that stone with homogenous structure are 
less fragile than stones with heterogeneous structure. Elastic module 
determine a stones resistance to shock wave induced deformation, 
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hardness determine a stone’s resistance to cavitation, microjet 
impact and fracture toughness determines a stone’s resistance to 
spalling damage and crack propagation. Calcium oxalate 
monohydrate and brushite stones are less fragile than magnesium 
ammonium phosphates and carboxy apatite stones because calcium 
oxalate monohydrate and brushite stones are stiffer, harder and more 
resistant to fracture. Based on the above factors, cystine stones are 
most ESWL resistant, next are brushite, and calcium oxalate 
monohydrate. 
HOW SHOCK WAVES BREAK STONES  
Numerous mechanisms by which shock waves may fragment 
stones have been described in the literature. Here, we give a 
synopsis of some of the most likely mechanisms. 
Spall Fracture:-  Spallation occurs after the shock wave enters 
the stone and subsequently reflects from the rear of the stone . The 
stone/urine interface inverts the large positive pressure pulse, 
resulting in a large tensile stress. This stress is added to the tensile 
stress of the still-incoming negative pressure tail, resulting in a very 
large tensile stress near the back wall.15,16 Most solids are much 
weaker in tension than in compression, and so the large tensile stress 
near the rear of the stone can be expected to make the material fail.  
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Shear Stress: Shear stresses will be generated by a 
combination of both shear waves and compressive waves that 
develop as the shock wave passes into the stone.17  Many materials 
are weak in shear, particularly like kidney stones if they consist of 
layers, as the bonding strength of the matrix between layers often 
has a low ultimate shear stress. Furthermore, the organic binder of 
kidney stones is much softer than the crystalline phase, and as the 
shock front passes through the stone, it will induce very large shear 
stresses at the binder/crystal interfaces, which likely contribute to 
the fracture of the kidney stone. Shear waves in the stone can also 
result in large tensile stresses that exceed the tensile stress induced 
by spallation.  
 
Fig-4: Schematic showing regions where different stone fracture 
mechanisms will act. 
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Superfocusing:  Superfocusing is the amplification of stresses 
inside the stone due to the geometry of the stone. The shock wave 
that is reflected at the distal surface of the stone can be focused 
either by refraction (associated with the high sound-speed and 
geometry of the stone) or by diffraction from the corners of the 
stone. It has been shown that these reflected waves can be focused to 
caustics (regions of high stress) in the interior of the stone and that 
this can lead to failure. The regions of high stress (both tensile and 
shear) can be determined from the geometry of the stone and its 
elastic properties (eg, density, longitudinal wave speed, and shear 
wave speed). 
Squeezing: Squeezing/splitting occurs because of the 
difference in sound speed between the stone (greater than 2,500 m/s) 
and the surrounding fluid (≈1,500 m/s). The shock wave inside the 
stone “runs away” from the shock wave propagating through the 
fluid outside of the stone. The shock wave that propagates in the 
fluid outside the stone results in a circumferential force on the stone 
(known as a hoop stress). This results in a maximum tensile stress at 
proximal and distal ends of the stone and leads to an axial “splitting” 
failure. It has been theorized that squeezing should be enhanced 
when the entire stone falls within the diameter of the focal zone, and 
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a lithotriptor based on this principal has recently been built and 
described in the literature. 
Cavitation: Cavitation refers to small bubbles (or cavities) that 
grow in the urine surrounding the stone in response to the large 
negative pressure tail of the acoustic pulse. When a cavitation 
bubble collapses near a solid surface (eg, a kidney stone) a microjet 
of fluid is formed that pierces the bubble and impacts the surface 
with speeds upwards of 100 m/s. This jet likely plays a role in 
cavitation-induced damage to kidney stones.18 The collapse of the 
cavitation bubble also results in the emissions of secondary shock 
waves that are radiated into the bubble. These secondary shock 
waves have an amplitude comparable to that of the focused shock 
wave. In vitro experiments where cavitation is suppressed show 
significant reduction in stone fragmentation. Cavitation is 
principally a surface-acting mechanism, and experiments indicate 
that it acts most strongly on the proximal (shock wave incident) 
surface of the stone. It has also been suggested that the stresses 
imparted by cavitation can act by a spall mechanism.Recent work 
has recognized that the cavitation generated by lithotriptors acts as a 
cluster of bubbles rather than individual bubbles, and that the 
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coherent collapse of the cluster may enhance the destructive power 
of cavitation.19 
Fatigue: Fatigue is a process that may occur anywhere in the stone. 
Its hallmark is the progressive development of cracks. The cracks are 
nucleated at sites of small imperfections that occur in almost all materials - 
these nucleation sites will be present in all kidney stones. The 
imperfections are sites of “stress concentrations” which, when a shock 
wave passes, can lead to local stresses far in excess of the average stress 
induced by the shock wave. With the impact of repetitive shock waves, the 
imperfections frow into microcracks. With subsequent shock waves, the 
microcracks grow into macrocracks, and eventually produce cracks large 
enough to induce failure. The cracks can be grown either by large tensile 
stresses or by large shear stresses. Therefore, fatigue will be enhanced 
wherever regions of high stress coincide with weak points in the stone. 
This means that there could be a synergistic effect between fatigue and 
some of the other mechanisms that result in localized regions of high 
tensile or shear stress. There are two pieces of evidence that strongly 
support the argument that stone comminution is a fatigue process. First, the 
internal structure of stones has been shown to affect how they fragment in 
lithotripsy.20 Second, normally more than 1,000 shock waves are required 
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to progressively fragment stones into sufficiently small pieces; the use of 
multiple stress cycles to fracture a material is a classic hallmark of fatigue. 
CHARACTERISTICS OF A LITHOTRIPTOR SHOCK WAVE 
A typical shock wave measured at the focus of a lithotriptor is 
shown in Fig.5.  
 
Fig 5. A pressure waveform measured at the focus of an 
electrohydraulic lithotriptor 
The wave is a short pulse of about 5 μs duration. Shock waves 
composed of positive compressive waves and negative tensile waves. 
Initial short and steep compressive front with pressures of about 40 
MPa that is followed by a longer, lower amplitude negative (tensile) 
pressure of 10 MPa, with the entire pulse lasting for duration of 4 μs. 
Note that the ratio of the positive to negative peak pressures is 
approximately 5. Pressure measurements near the focal region of a 
Dornier unmodified HM3 indicate a 6-dB beam, of a width of 
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approximately  15 mm. Since most of renal and ureteric stones are 
also generally of this dimension, the wave front incident on the stone 
can be considered a plane wave. 
 
Fig 6. Focal waveforms measured in the electrohydraulic 
lithotripter (Dornier HM3) and an electromagnetic lithotripter  
(Storz SLX Energy 9). 
 
In Fig 6 we compare waveforms measured in an 
electrohydraulic lithotripter (Dornier HM3) and an electromagnetic 
lithotripter  (Storz SLX Energy 9).  It shows that the  features of  
waveform are similar regardless of the type of lithotriptor, but there 
are considerable differences in the amplitude and spatial extent of 
the acoustic output.  . It is likely that the amplitude and size of the 
focal zone of different lithotriptors affects their performance. 
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Roentgenography has played a major role in the diagnosis and 
management of calculus disease. Various researchers have attempted 
to predict the stone composition by different methods. 
In 1996 Dretler and Koff 21 further analyzed radiographic 
patterns of calcium oxalate dihydrate and monohydrate stones. 
Smooth edge, denser than bone, homogenous are pure calcium 
oxalate monohydrate stones. Radial striations and superimposed 
stippling pattern in calcium oxalate dihydrate stones. This study is 
the first proof that radiographic morphology can be related to ESWL 
stone free rate.    
EXTRACORPOREAL SHOCK WAVE IN THE TREATMENT 
OF URETERIC CALCULI 
Chaussy and his colleagues initially treated ureteric stones 
insitu and reported < 50% success rate. Most of the stones had been 
disintegrated, but the pieces were held together by edematous 
mucosa. This was seen in patients with stones impacted. This 
observation led Chaussy to use an ureteric catheter or an 
ureteroscope to push the ureteric stone into the renal collecting 
system. The success of this treatment was 75 - 95%. 
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ASSESSMENT OF FRAGMENTATION 
One of the troublesome aspect of ESWL is determining the 
adequacy of fragmentation. One of the best indications is dispersion 
of sand, but this can occur only if the stone is located in a large 
cavity such as renal pelvis. Barr et al 1990 noted that both Calyceal 
and Ureteric stones may be fragmented satisfactorily, but 
radiographic appearance may appear unchanged. Hence even if the 
24-hour post treatment plain radiograph shows no definite 
pulverization the patient should be followed for a couple of weeks 
before considering retreatment.  
IMPACTED URETERIC STONES 
An impacted stone may be defined as a stone that cannot be 
bypassed by a wire or catheter or a stone that remains at the same 
site in the ureter for more than 2 months.  The presumed action of 
shockwaves on a stone is the creation of interacting compressive and 
tensile forces at fluid stone interfaces. Stone fragment is torn off in 
layers. Green and Lytton, 1985 22 & Farsi et al 23, 1994 in their study 
noticed that impacted stones are often more resistant to 
fragmentation by ESWL. One explanation for this observation is 
expansion space theory the initial shock waves remove an outer layer 
of stone material, but the surrounding ureteric walls do not allow 
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these particles to fall away. The new fluid –stone interfaces interfere 
with the transmission of next series of shock waves to the core of the 
stone, thereby preventing complete fragmentation. This situation can 
be remedied by push back to kidney with a ureteric catheter or 
ureteroscope, by bypassing the stone with a ureteric catheter to 
provide an artificial expansion space, or by irrigating the stone 
during insitu ESWL using saline to flush the particles away from the 
solid core. The only disadvantage to ureteric irrigation is that renal 
pelvic pressure may raise enough to result in forniceal tear and 
extravasation. 
Although these reports suggest that ureteroscopy may be the 
optimal approach to the impacted ureteric stone, some urologists still 
favor SWL as the initial approach for stones smaller than 1 cm in the 
ureter. However, ureteroscopy may be the treatment of choice for 
patients whose SWL treatment failed, for patients with cystinuria, 
for patients with distal obstruction, for patients with impacted 
stones, for obese patients, for patients with bleeding diathesis, and 
when SWL is not readily available. 
Under the sage leadership of the late Dr. Joseph W. Segura, the 
AUA Practice Guidelines Committee suggested to both the AUA and 
the EAU that they join efforts in developing the first set of 
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internationally endorsed guidelines focusing on the changes 
introduced in ureteral stone management over the last decade.  
This joint EAU/AUA Nephrolithiasis Guideline Panel – 
200724 performed a systematic review of the English language 
literature published since 1997 and a comprehensively analyzed 
outcomes data from the identified studies. Based on their findings, 
the Panel concluded that when removal becomes necessary, SWL 
and ureteroscopy (URS) remain the two primary treatment 
modalities for the management of symptomatic ureteral calculi. 
Other treatments were reviewed, including medical expulsive 
therapy (MET) to facilitate spontaneous stone passage, percutaneous 
antegrade ureteroscopy, and laparoscopic and open surgical 
ureterolithotomy. 
Procedures per patient were counted in three totals: primary 
procedures, secondary procedures, and adjunctive procedures. 
Primary procedures were all consecutive procedures of the same type 
aimed at removing the stone. Secondary procedures were all other 
procedures used to remove the stone. Adjunctive procedures were 
defined as additional procedures that do not involve active stone 
removal. 
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Analyses were performed for the following patient groups: 
1. Proximal stones ≤10 mm 
2. Proximal stones >10 mm 
3. Proximal stones regardless of size 
For Ureteral Stones <10 mm: 
Standard: Patients should be followed with periodic imaging studies 
to monitor stone position and to assess for hydronephrosis. Stone removal 
is indicated in the presence of persistent obstruction, failure of stone 
progression, or in the presence of increasing or unremitting colic. 
For Ureteral Stones >10 mm: 
Although patients with ureteral stones >10 mm could be 
observed or treated withMET, in most cases such stones will require 
surgical treatment. 
Standard: A patient must be informed about the existing active 
treatment modalities, including the relative benefits and risks 
associated with each modality. 
Recommendation: For patients requiring stone removal, both 
SWL and URS are acceptable first-line treatments. Routine stenting 
is not recommended as part of SWL. 
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The current meta-analysis analyzed SWL stone-free results for three 
locations in the ureter (proximal, mid, distal). The SWL stone-free results are 
82% in the proximal ureter (41 studies, 6,428 patients), 73% in the mid ureter 
(31 studies, 1,607 patients), and 74% in the distal ureter (50 studies, 6,981 
patients). The results in the 1997 guideline, which divided the ureter into 
proximal and distal only, reported SWL stone-free results of 83% and 85%, 
respectively. The Confidence Intervals for the distal ureter do not overlap and 
indicate a statistically significant worsening of results in the distal ureter from 
the earlier results. No change is shown for the proximal ureter. The cause of 
this difference is not clear. Additional procedures also were infrequently 
necessary (0.62 procedures per patient for proximal ureteral stones, 0.52 for 
mid-ureteral stones, and 0.37 for distal ureteral stones). 
Serious complications were again infrequent. As expected, stone-free 
rates were lower and the number of procedures necessary were higher for 
ureteral stones >10 mm in diameter managed with SWL. 
The newer generation lithotriptors with higher peak pressures 
and smaller focal zones should, in theory, be ideal for the treatment 
of stones in the ureter but instead have not been associated with an 
improvement in stone-free rates or a reduction in the number of 
procedures needed when this treatment approach is chosen. 
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SUCCES OF ESWL 
In a large series by Taku Abe et al 25 with a total of 2844 
patients (3061 renal units) after  follow up period of 3 months 
defined stone free as having no stone material radiographically or 
ultrasonographically, and success was defined as being stone free or 
having residual fragments ≤ 4 mm in diameter. They also defined 
recurrence of calculi as radiologic or ultrasonographic evidence of 
an upper urinary tract stone on the ipsilateral side. 
CONTRAINDICATIONS TO ESWL 
Absolute  
 Pregnancy 
 Uncorrected bleeding disorder 
 Active sepsis or untreated urinary tract infection 
 Untreated obstruction distal to the stone  
Relative  
Stone Factors:  
 Size - large stones > 2cm maximum diameter or staghorn 
 Location: lower calyceal, especially if > 1cm 
 Number: more than 1, especially if large or in different locations 
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 Composition: hard stones such as calcium oxalate 
monohydrate, calcium phosphate or cystine 
 Previous failed SWL for same stone 
Patient Factors 
 Obesity 
 Uncontrolled hypertension 
 Proximate aneurysms 
 Cardiac pacemakers 
 Significant cardiopulmonary disease 
 Inability to be properly positioned (i.e. Orthopedic deformity) 
 Severe gastrointestinal disease 
 Impaired cognitive ability 
COMPLICATIONS 
The ultimate goal of ESWL is to fragment renal and ureteric 
calculi as effectively as possible with minimizing the potential injury 
to surrounding tissues. Most SWL complications are minor and self-
limiting, such as transient hematuria, pain, nausea and vomiting, 
there are also life threatening case reports described in the 
literature.26 
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Steinstrasse 
Post-SWL urinary obstruction owing to ureteral impaction of 
fragments is referred to as steinstrasse, or “street of stone,” which 
connotes the classic radiographic findings. Steinstrasse occurs in up 
to 15% of radiography obtained within 48 h of SWL, and is found 
most commonly in the distal one-third of the ureter. Up to 50% of 
patients found to have steinstrasse require intervention, which most 
often involves either placement of a percutaneous nephrostomy tube 
or repeat ESWL.27 
Coptcoat and associates classified Steinstrasse into three 
subtypes.28   Type I consists of a column of dust or gravel, and is the 
most common type. Type II is caused by an impacted large “lead 
fragment” with dust or gravel stacked behind it. Type III refers to a 
column of large fragments.  
The initial management of symptomatic Steinstrasse consists 
of hydration and analgesia. Persistent obstruction requires the 
placement of a percutaneous nephrostomy tube. Middle or upper 
pole access is preferred in case an antegrade approach is needed. 
Ureteral stent placement can be difficult and dangerous because the 
ureter is acutely inflamed and often tightly impacted with fragments. 
Subsequent intervention for failed conservative management is 
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tailored to the type of steinstrasse. Most type I steinstrasse will pass 
with nephrostomy placement alone, which relieves the acute 
obstruction and, in turn, restores ureteral peristalsis. Type II 
steinstrasse may need repeat SWL or ureteroscopic lithotripsy to the 
lead fragment. Type III steinstrasse will need definitive management 
with SWL, ureteroscopy, or a percutaneous approach, depending on 
the location and stone burden. Open surgery has been required in 2–
4% of patients with symptomatic steinstrasse. Preoperative 
placement of a ureteral stent may reduce the incidence of 
steinstrasse. 
In 400 patients randomized to stent or none before SWL for 
1.5–3.5-cm renal calculi, the incidence of steinstrasse was 6% and 
12%, respectively.29 However, according to the authors, stenting did 
not seem to alter the presentation, treatment, or outcome of 
steinstrasse. As an adjunct to endoscopic management of severe 
steinstrasse, ureteral meatotomy has been employed by the authors. 
Using a wide “cutting” incision of the ureteral orifice and judicious 
“spot” fulguration as needed, this technique provides improved 
ureteral drainage and easier ureteral access, and is particularly useful 
when multiple procedures for steinstrasse are anticipated. Resultant 
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vesicoureteral reflux has not been found to be an issue in our 
experience. 
In a series of 1,130 ureteral stone SWL treatments Coz et al 
reported no complications. 30 In a series of 442 patients Park et al 
reported that 3 had steinstrasse, 10 had fever and 10.5% experienced 
pain.31 In a review of complications in SWL series comprising 100 
or more procedures published since 1998 with a total of 1,683 cases 
showed that the overall incidence of major and minor complications 
was 0.36% and 5.8%, respectively. 32 These results suggest that 
complications occur more in patients in whom SWL fails. These 
patients typically have larger stones and multiple treatment sessions. 
In a randomized outcomes trial of ureteral stents for 
extracorporeal shock wave lithotripsy of solitary kidney or proximal 
ureteral stones by Chandhoke P S et al 33 concluded that size 4.7Fr 
stents may be preferable over 7Fr stents when used in conjunction 
with shock wave lithotripsy. 
George haleblian et al 34 in a systematic review ureteral 
stenting and urinary stone management concluded that stenting is not 
mandatory after uncomplicated simple ureteroscopy and shock wave 
lithotripsy. Patients with stents seem to have significantly more 
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bladder and lower urinary tract symptoms than those in whom stents 
are not placed. However, there is a subgroup of patients who likely 
benefit from stenting following a procedure because of the increased 
risk of complications. The ideal ureteral stent biomaterial has yet to 
be discovered and an area of promising development is the drug 
eluting stent to prevent infection and encrustation. 
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MATERIALS AND METHODS  
PERIOD OF STUDY 
January 2009 – April 2011 
STUDY DESIGN  
Prospective study 
SOURCE OF PATIENTS 
The study was conducted in the Department of Urology, Rajiv 
Gandhi Government General Hospital and Madras Medical College, 
Chennai from the patients who reported for the management of upper 
ureteric calculus.  
Guidelines of the ethics committee were followed. All the 
patients were informed about the study and a consent form was 
signed by them. A previously designed proforma was filled to 
recorded data. 
METHOD OF STUDY 
All the patients were explained about the available modalities 
of treatments and their complications in the management of upper 
ureteric calculus – Medical Expulsion Therapy, Ureteroscopy with 
Intracorporeal Lithotripsy, Extracorporeal Lithotripsy, Percutaneous 
Nephrolithotomy and Open Surgery. 
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PATIENT EVALUATION 
A detailed history and a clinical examination was performed 
followed by baseline investigations including complete blood count, 
blood  sugar, urea, serum creatinine,  urine routine including  culture 
and sensitivity were done in all patients. A plain X ray KUB and 
Ultrasound  were done in all patients. Either Intravenous Urogram or 
Contrast Enhanced CT KUB was done as a functional study. 
 Stone size measurements taken in the study – largest 
dimension in plain X ray KUB and  Ultrasound.  
INCLUSION CRITERIA 
1) Patients with unilateral upper ureteric calculus willing for 
extracorporeal shockwave lithotripsy. 
2) Patients with normal renal parameters. 
3) No previous treatments for the same ureteric calculus. 
4) No anatomical anomalies in the urinary tract. 
EXCLUTION CRITERIA 
1) Not willing for ESWL 
2) Bilateral ureteric calculi 
3) Coagulation disorder/patients on anticoagulation drugs 
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4) Pregnancy 
5) Sepsis 
6) End stage renal disease 
Three hundered patients selected were divided into two equal 
groups of 150 each during the period, January 2009 to April 2011. 
The patients were divided into two groups, Group A and Group B. 
They were offered two folded pieces of paper bearing letter A or B 
and were requested to take one of these. Those who picked A were 
included in group A and selected for ESWL with DJ stent and those 
who picked B included in group B were given in situ ESWL without 
DJ stent. 
In the patients selected for DJ placement a prophylactic 
injection of gentamycin 80 mg IM was given one hour prior to the 
insertation DJ stent and then a 5 Fr 26 cm DJ stent was placed under 
local, regional  or general anaesthesia before ESWL. 
PATIENT PREPARATION & TECNIQUE OF ESWL 
Bowel preparation with anti flatulent & laxatives a day before 
procedure.  
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POSITION OF PATIENT 
Supine 
ANAESTHESIA/ANALGESIA 
Inj.Pentazocine 30 mgs and Inj.Promethazine hcl 25 mgs 
intramuscularly 30 minutes before the procedure. 
TECNIQUE OF ESWL 
All treatments were done with Donier Compact Delta II 
(Electromagnetic Generator) device as outpatient procedure. 
Stone was localized with fluoroscopy. 
2500 shockwaves were given. The energy intensity was kept 
between 4 and 5 and the shockwave rate was 60 per minute. 
POST PROCEDURE 
After each session of treatment patients were observed for 2-3 
hours and allowed to go home. Patients were explained about the 
post treatment hematuria, dysuria and passage of stone fragment in 
the urine. Patients advised to maintain adequate oral fluids.  
FOLLOWUP 
Patients were followed up at 15 days, 30 days, 60 days and in 
90 days or whenever patients had unusual urinary complaints after 
the procedure.  
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Failure was defined as the presence of fragments of any size in 
the follow-up film 3 months after the final ESWL session. 35 
Although history, physical examination, Ultrasound KUB, X 
ray KUB was  done during all visits, a plain X-ray film was used as 
the standard method to identify residual fragments. The treatment 
protocol included a second session of ESWL and if necessary a third 
session of ESWL. The patients follow up was terminated if the 
patient cleared the stone with ESWL or a secondary treatment was 
selected for the failure of ESWL. 
For each group, hematuria, fever, steinstrasse, ureteric colic 
requiring hospital admissions, lower urinary tract symptoms, stone 
clearance, number of ESWL sessions, and secondary procedures 
were recorded. The DJ stent was removed when the stone 
disappeared or at three months whichever is earlier. 
STUDY ANALYSIS 
Data was analyzed using SPSS (V: 17) software. 
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OBSERVATION & RESULTS 
The study comprised of 300 patients of upper ureteric calculus 
divided into two groups, 150 patients in each group. Group A 
comprised of pre ESWL stented patients and group B were non-
stented patients who had satisfied the inclusion and exclusion 
criteria. 
AGE DISTRIBUTION 
Age of the patients ranged from 17-70 yrs and most patients 
were in 21-40 years of age. 
Table-1: Showing age distribution in both age groups 
  
AGE (YRS) 
NO. OF PATIENTS 
STENTED NON-STENTED 
<20 2 4 
21-40 94 96 
41-60 41 47 
>60 13 3 
TOTAL 150 150 
P=0.06    not significant 
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SEX DISTRIBUTION 
There were 114 male and 36 female patients in group A and 
118 males and 32 females in group B our study. 
Table 2.  Showing sex distribution in both age groups 
 
 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED 
MALE 114 118 232   (77.3%) 
FEMALE 36 32 68    (22.6%) 
TOTAL 150 150 300 
P=0.581  not significant 
SIDE DISTRIBUTION 
Left side stones predominated over right sided stones in both 
group A and B.  
Table-4:  Showing side distribution in both age groups 
SIDE 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED 
RIGHT 71 73 144 (48 %) 
LEFT 79 77 156 (52%) 
P=0.817 not significant    
 43
STONE SIZE DISTRIBUTION 
In our study size of the upper ureteric calculus range from 
8mm-19mm. Both group A and Group B were matched to their stone 
sizes. 
Patients with stone size of 8 – 13 mm were 100 patients in 
each group and patients of stone size between 14 – 19 mm were 50 
patients in each group. 
Table-3: Showing stone size in both age groups 
SIZE 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED 
8 - 10mm 45 45 90 (30.0%) 
11 - 13mm 55 55 110 (36.6%) 
14 – 16mm 35 35 70 ( 23.3%) 
17 - 19mm 15 15 30 ( 10.0%) 
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PRIMARY TREATMENT 
In our study overall stone-free rate at three months was 90.6% 
(272/300). Clearance after first sitting was 56.3% (169/300), after 
second sitting was 29.0% (87/300) and after third sitting was 5.3% 
(16/300).  
Table-5: Showing number of sittings in both age groups     
NO. OF 
SITTINGS 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED 
ONE 79 (52.6%) 90 (60.0%) 169 (56.3%) 
TWO 41 (27.3%) 46 (30.6%) 87 (29.0%) 
THREE 11 (7.3%) 5 (3.3%) 16 (5.3%) 
TOTAL 131 (87.3%) 141 (94.0%) 272/300 
(90.6%) 
P=  0 .235  not significant 
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PRIMARY TREATMENT 
The patients were categorized according to stone size and the 
number of sittings they under went in the table below. 
Table-6: Showing number of sittings according to stone size in 
both age groups. 
SIZE OF 
CALCULU
S 
NO. OF PATIENTS 
TOTA
L 
STENTED NON-STENTED 
1st 
sittin
g 
2nd 
sittin
g 
3rd 
sittin
g 
1st    
sittin
g 
2nd 
sittin
g 
3rd 
sittin
g 
8-10mm 34 8 3 39 6 0 90/300
11-13mm 35 11 9 38 14 3 110/30
0 
14-16mm 9 16 10 11 18 6 70/300
17-19mm 1 6 8 2 8 5 30/300
TOTAL 79/15
0 
41/15
0 
30/15
0 
90/15
0 
46/15
0 
14/15
0 
 
I – SITTING     P=0.963 not significant 
II – SITTING    P=0.858 not significant 
III– SITTING    P=0.540 not significant 
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PRIMARY TREATMENT 
The patients who underwent three sittings of ESWL and 
became stone free were named as success and those who did not 
become stone free after three months and/or needed any other 
ancillary procedures were named as failure of ESWL. Of the stented 
group 11 patients were stone free and 19 patients failed to ESWL 
therapy. Where as in the non-stented group 5 patients had a 
successful ESWL therapy and 9 patients failed to ESWL.  
Table- 7: Showing the success of rate after 3rd sitting of ESWL 
SIZE OF 
CALCULUS 
NO. OF PATIENTS 
STENTED NON-STENTED 
SUCCESS FALIURE SUCCESS FALIURE
8-10mm 1 2 0 0 
11-13mm 2 7 1 2 
14-16mm 4 6 2 4 
17-19mm 4 4 2 3 
TOTAL 11 19 5 9 
STENTED - P=0.686  not significant 
NON STENDED - P=0.969  not significant 
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STONE FREE RATE – SIZE 
Clearance according to size: 8mm to 10mm were 97.7%, 11mm 
to 13mm were 91.8%, 14mm to 16mm were 85.7% and 17mm to 
19mm were 76.6%. 9.3% patients did not have successful outcome. 
Of these, 7% cases had incomplete fragmentation and were termed as 
SWL failures. They required auxiliary procedures in the form of 
open ureterolithotomy for two cases and nineteen cases (6.3%) 
underwent  ureteroscopy. The remaining seven  cases had effective 
fragmentation but incomplete clearance and underwent URS with 
stone extraction for the same.    
Table – 8:  Stone free rate according to stone size 
SIZE 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED
8-10mm 43/45 (95.5%) 45/45(100%) 88/90 (97.7%) 
11-13mm 48/55 (87.2%) 53/55 (96.3%) 101/110 (91.8%)
14 – 16mm 29/35 (82.8%) 31/35 (88.5%) 60/70 (85.7%) 
17 – 19mm 11/15 (73.3%) 12/15 (80%) 23/30(76.6%) 
TOTAL 131/150 (87.3%) 141/150 (94%) 272/300 (90.6%)
P = 0.015, Significant 
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COMPLICATIONS 
Post SWL complications consisted of 17 (5.6%) patients with 
hematuria, fever in 9 (3%) patients which was treated with culture 
specific antibiotics, steinstrasse in 17 (5.6%) patients and ureteric 
colic requiring hospital admissions 15 (5%) patients. All the colic 
patients had stone size larger than 13 mm.  
Table- 9: Showing the complications in both age groups. 
COMPLICATIONS 
NO. OF PATIENTS 
TOTAL 
STENTED NON-STENTED 
HAMATURIA 14(9.3%) 3(2.0%) 17 (5.6%) 
FEVER 7(4.6%) 2(1.3%) 9 (3.0%) 
STIENSTRASSE 9 ( 6%) 8 (5.3%) 17 ( 5.6%) 
URETERIC COLIC 1 ( 0.6%) 14 (9.3%) 15 ( 5%) 
P=0.000 significant 
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COMPLICATIONS - LUTS 
Among the lower urinary tract symptoms (LUTS), frequency 
was seen in 75 (25%) cases, urgency in 84 (28%) cases, dysuria in 
109 (36%) cases and nocturia in 21 (7%) cases. Most of the lower 
urinary tract symptoms were seen in stented (group A) patients.  
Table-10: Showing the incidence of LUTS in both age groups. 
LUTS 
NO. OF PATIENTS 
TOTAL STENTED 
n = 150 
NON-STENTED 
n =150 
FREQUENCY 64 (42.6%) 11 ( 7.3%) 75 (25%) 
URGENCY 69 (46%) 15 (10%) 84 (28%) 
DYSURIA 86 (57.3%) 23 (15.3%) 109 (36%) 
NOCTURIA 17 (11.3%) 4 ( 2.6%) 21 (7.0%) 
Since P=0, Frequency Vs stented with Non stented, Significant  
Since P=0, Urgency Vs   stented with Non stented, Significant  
Since P=0, Dysuria Vs stented with Non stented, Significant  
Since P=0.162, Nocturia Vs stented with Non stented, Not Significant 
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STATISTICAL ANALYSIS OF RESULTS 
The SPSS Version 17 package was employed to find Pearson’s                 
chi-square test and Fisher’s exact chi-square test for the statistical 
analysis. 
Table 1 - Table 7, shows that there is no association between 
age group, sex, side and  number of sittings in the  success of ESWL 
among  stented  and  non-stented patients, since P values are greater 
than 0.05. 
Table 8, infer there is significant association in the stone free 
rate among stented and non-stented group since P values are less 
than 0.05. 
Table 9-10, also shows that there is significant association in 
the complication (P=0.000) and LUTS (P=0) among stented and  
non-stented  group of patients.   
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DISCUSSION 
ESWL has revolutionized the treatment strategy of urolithiasis 
world wide and continue to be a major therapeutic modality for 
treating the majority of upper urinary tract stones.  Its non invasive 
nature along with high efficacy has resulted in outstanding patient 
and surgeon acceptance. 
ESWL and ureteroscopy used in the management of upper 
ureteric stones have valid advantages and disadvantages. Supporters 
of ESWL claim that it is effective and noninvasive, is associated 
with less morbidity, requires lesser anesthesia than ureteroscopy, and 
seldom requires ureteric stents. Critics argue that the success rates 
are not as high as those of ureteroscopy, equipment availability may 
be limited, visualization of the stone is often difficult, attainment of 
a stone-free state requires a longer time and follow-up, re-treatment 
rates are higher, and costs are higher. Supporters of ureteroscopy 
claim that it is highly successful and minimally invasive, is 
associated with minimal morbidity, can be used with larger and 
multiple stones, and has high immediate stone-free rates. Critics 
argue that it requires specialized training, requires more anaesthesia, 
and more often requires ureteric stent placement. 
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We had an overall stone-free rate of 90.6%. This result 
compares favorably with previously published series and is a timely 
reminder that good stone-free rates can be achieved without the use 
of ureteroscopy. Previous studies with different lithotriptors reported 
success rates between 80-90%. 36  In the study of Gnanapragasam et 
al. 37 , stone-free rates for upper ureteric stones were 90%. Failure of 
ESWL was seen in patients with stone size >1.3 cm. Similarly, 
Mogensen and Anderson 38 reviewed outcomes of 199 patients with 
ureteric stones treated with SWL. Stone-free rates at three and six 
months after SWL for upper ureteric stones were 86% and 91% 
respectively.  
Hofbauer et al. 39 evaluated the outcome of 1259 ureteric 
stones with success rate of upper ureteric stones being 98%. We had 
retreatment rate of 59% and auxiliary procedures were required in 
8% cases. Fetner et al 40 found a statistically significant relation 
between stone size and success rate. The American Ureteral Stones 
Clinical Guidelines Panel  reported that, for proximal ureteric stones, 
the success rate of SWL was 87% for <1 cm stone and 76% for >1 
cm stone. In our study 95% success was seen in cases with <1 cm 
stone while 85% success was seen in >1 cm stone. This success rate 
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may be due to better stone localization techniques and use of 
standard lithotripter (Dornier Delta II lithotripter). 
Pushback technique was not used in any of our patients. All 
stones were treated without manipulating the position of the stone. 
There is no significant difference in success rates for in situ versus 
pushback ESWL. 41 Macroscopic expansion space is not required for 
successful fragmentation of ureteric calculi.42 Ureteral manipulations 
using pushback technique are associated with 5.1% perforation rate. 
We also observed that the presence of DJ stents significantly reduces 
the success rates. DJ stents were inserted in 150 cases preoperatively 
of which eight (20%) patients required auxiliary procedure in the 
form of ureteroscopy. Ryan et al 43 showed that in situ ureteric stents 
impair ureteric peristalsis and trap large fragments thus delaying 
stone clearance. Presence of DJ stent next to the stone may prevent 
full impact of the shock wave on the stone. However, DJ stents are a 
must in stones causing severe obstruction or solitary functioning 
renal unit. 44 
Several authors have attempted to identify predictive factors 
associated with the failure of ESWL treatment for ureteric stones. 
Abdel-Khalek et al 45 in a study of 938 patients, defined a stone 
transverse diameter of > 10 mm, site of stone and presence of a stent 
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as predictors of failure of ESWL. Kim et al 46 in a study of 369 
patients investigating factors that influence fragmentation of ureteric 
stones, reported as such the size of stone, radio-opacity and degree 
of obstruction, but not the location. In a study by Pareek et al 47 
identified increased body mass index (BMI) and a high Hounsfield 
units (HU) value as independent predictors of the results of ESWL 
for upper urinary tract stones, and devised an equation to compute 
the probability of treatment failure, which was 1/1 + 2.7(– z), where 
Z = 0.294 BMI + 0.13 HU – 18.98. 
Ureteric stents are significant tools in the management of 
upper urinary tract conditions. In the context of stone disease, 
ureteric stents are usually inserted in cases of obstruction in a 
solitary kidney, patients with obstruction and fever at risk of sepsis, 
prolonged pain and to prevent deterioration of renal function. 
Furthermore, their use is common practice in cases where large 
stones (usually > 20 mm) are treated by ESWL, and for managing 
steinstrasse and/or obstruction after ESWL. 
The possible effect of the presence of a stent in ESWL has 
been an issue of long-standing debate. Initially, it was thought that 
stents might contribute to successful stone passage. Bierkens et al 48 
randomized 64 patients with large renal stones (but no ureteric 
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stones) and found a difference in the stonefree rate in 3 months of 
9% in favour of the stented population (44% vs 35%), while Pryor 
and Jenkins 49 found a difference of 18% in the stone-free rate in 
favour of the unstented patients with ureteric stones. Later studies of 
stents and ureteric stones suggested that they do not affect the final 
stone-free rate. Stents are associated with significant morbidity, 
including discomfort and irritative symptoms, and recent reports on 
the outcome of ESWL are contradictory. El-Assmy et al 50 
randomized 186 patients with ureteric stones and moderate/severe 
hydronephrosis, and the results were better but not statistically 
significant for the unstented patients (91% vs 85% stone-free rate,  
P = 0.25), while Musa 51 in 120 patients with renal stones found a 
stone-free rate of 91% vs 88% in favour of the unstented population 
an also found  there was slightly higher incidence of fever in stented 
patients. This could be explained by the fact that patients with DJ 
stent had two additional procedures performed and a foreign body 
was placed in a normally sterile system. 
In a study by Khaled in the risk factors for the formation of a 
steinstrasse after extracorporeal shock wave lithotripsy, the overall 
incidence of steinstrasse was 3.97%.52 Stone size and site, renal 
morphology and shock wave energy are the significant predictive 
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factors controlling steinstrasse formation. If a patient has a high 
probability of steinstrasse formation, close followup with early 
intervention or prophylactic pre-ESWL ureteral stenting is indicated. 
Multiple large series have shown overall stone-free rates of 
more than 80% when considering SWL for proximal ureteral stones. 
A series of 397 upper ureteral stones treated with a Modulith SL-20 
lithotriptor. Of the stones treated 91% were 14 mm or less in 
diameter and the stone-free rate was 84.3% at 3-month followup. 
Stent-related symptoms have a high prevalence and may affect over 
80% of patients. They include irritative voiding symptoms including 
frequency, urgency, dysuria, incomplete emptying; flank and 
suprapubic pain; incontinence, and hematuria. Assessment tools are 
important to determine their intensity and allow for comparisons 
between different points in the timeline. The Urinary Stent Symptom 
Questionnaire (USSQ) is the most proper tool used for this purpose. 
Management should be focused on the prevention and management 
of symptoms. In this sense, research has focused on new materials 
and stent designs that would be more compatible to the physiologic 
properties of the urinary tract and medications that can ameliorate 
the sensitivity and motor response of the bladder.53 
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Our results also show that the presence of a ureteric stent is 
associated with a higher failure rate of ESWL for ureteric stones. 
This might be for several reasons, such as difficulties in targeting, 
energy loss and the effect of the stent on peristaltic movements of 
the ureter, leading to reduced clearance of fragments. Ureteric stents 
should still be used in cases of sepsis, and in patients with 
deteriorating renal function due to obstruction or those with 
intolerable pain. However, the routine use of ureteric stents in 
patients offered ESWL for ureteric stones, irrespective of size or 
position in the ureter, should be considered with caution. 
Although most SWL complications are minor and self-limiting, 
such as transient hematuria, pain, nausea and vomiting, there are 
also life threatening  case reports described in the literature. In a 
study by Nazim Mohayuddin et al 54 the lower urinary tract 
symptoms e.g urinary frequency, nocturia, urgency, dysuria and 
haematuria were  quite high in the stented group  (45%, 12.5%, 
47.5%, 57.5%, 92.5.%) as compared to  the non – stented group  
(7.5%, 2.5%, 10%, 15%, 67.5%) respectively. This  similar findings 
were noted in the other studies e.g Perminger et al 55 found a higher 
incidence of LUTS in patients with DJ stents than in the control 
group (43% vs 25%). Similarly in the study by Paramjit S 51 et al the 
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incidence of frequency, urgency, dysuria was higher in the stented 
group. The same finding were reported by Musa who found a much 
higher frequency of lower urinary tract symptoms (85%) in the 
stented group as compared to the non stented group. It was suggested 
that the stent related LUTS were due to the presence of foreign body 
in the urinary bladder irritating the trigone and the bladder neck. 
Islam AG 56 in a study with 60 patients concluded that no significant 
difference statistical difference was oberseved in stone free rate 
between stented and non-stented groups, but patients in the stented 
group had significant side effects predominantly dysuria, urgency, 
frequency and suprapubic pain which was attributed to the stent. 
In our study, the stented group of patients had more lower 
urinary tract symptoms than the non – stented group of patients. 
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CONCLUSION 
1) Treatment with ESWL has a low morbidity and high 
effectiveness. 
2) Pre ESWL ureteral stenting provides no additional benefit over 
in situ ESWL. 
3) Uretral stents are associated with significant patient discomfort 
and morbidity. 
4) Although ureteral stents are associated with more irritative 
symptoms, their use resulted in fewer hospital readmissions 
compared to when no stent was used to treat upper ureteric 
calculus. 
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S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
1 42/F LT 8 x7 Done 1 D
2 32/F RT 9x11 Not done 1 F,U
3 39/M RT 16x11 Done 1 F,U,D
4 60/M RT 19x17 Not done 3
5 26/M LT 12x11 Done 1
6 54/F LT 12x11 Not done 1
7 40/F RT 10x9 Done 2 F,U,D,N
8 60/M RT 15x10 Not done 1 F,U,D,N
9 21/M LT 8x7 Not done 1
10 60/F RT 10x8 Done 3 URS&ICL U,D
11 34/M LT 9x8 Done 1 D,N
12 47/M LT 10x9 Not done 1
13 45/M RT 9x11 Not done 1
14 28/F LT 14x15 Done 3
15 30/F RT 11x9 Done 1 D
16 65/M RT 10x11 Done 1 F,U,D
17 27/M RT 9x8 Done 1 F,U,D
18 40/M RT 8x11 Done 1 D
19 45/F LT 9x8 Not done 1
20 39/F LT 9x8 Done 1 D
21 55/M LT 11x12 Not done 2 F,U,D
22 35/M RT 8x5 Done 1 D
23 18/F RT 8x5 Done 1
24 51/M LT 11x10 Done 3 URS&ICL F,U,D,N
25 25/M LT 9 X8 Done 2 D
26 40/M LT 8 x7 mm Not done 1
27 23/M LT 8 X 9 Not done 1
28 30/M RT 19 X 18 Done 3 URS&ICL D
29 60/M LT 10 X 9 Done 1 U,D
30 24/M LT 9 X 8 Not done 1
31 40/M RT 9 X8 Done 1
32 34/M LT 8 X9 Not done 2
33 35/M LT 11 X13 Done 3 URS&ICL F,U,D
34 52/M LT 1X0.9 Not done 1
35 40/M RT 9 X8 Done 1 F,U,D
36 44/M RT 11 X10 Not done 1 D
37 33/M RT 11 X9 Not done 3
38 38/F LT 8 X9 Done 1 D,N
39 62/M RT 14 X 11 Not done 2 F,U,D
40 42/M LT 11 X 9 Not done 1
41 51/F LT 11 X10 Done 3
42 34/M RT 10 X9 Done 2 D
43 25/F LT 9 X8 Not done 1
44 34/F LT 9 X10 Done 1 F,U,D
45 62/M LT 10 X11 Done 1 F,U,D
46 29/M RT 11 X13 Done 3
47 30/M RT 8 X 9 Not done 1
48 52/M RT 11 X13 Done 2 F,U,D
49 30/M RT 11 X 13 Not done 1
50 24/M LT 8 X 9 Done 1
MASTER CHART
S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
51 38/M LT 16 X13 Done 2 D
52 20/M LT 15 X12 Not done 3 URS&ICL F,U,D,N
53 52/M LT 8X 9 Not done 1
54 32/M RT 14 X11 Not done 3 F,U,D
55 77/M RT 13 X11 Not done 1
56 35/M RT 13 X11 Done 2 F,U,D
57 40/M RT 14 X 10 Not done 1 D
58 53/M RT 8 X9 Not done 1
59 45/M LT 15 X11 Not done 2 F,U,D,N
60 59/M RT 16 X10 Done 3 U,D
61 43/M LT 8 X9 Done 1
62 41/F LT 8X9 Not done 1
63 31/M LT 10 X9 Done 1
64 36/F RT 11 X10 Done 1 F,U,D
65 29/F RT 10X12 Done 1 D
66 28/M LT 8 X9 Not done 1
67 35/F RT 10 X9 Not done 1
68 58/M LT 11X13 Done 1 F,U,D
69 23/F RT 8 X9 Done 3
70 40/M RT 11X 10 Done 1 F,U,D
71 47/F LT 8 X9 Not done 1
72 45/M RT 11X10 Not done 1
73 56/M LT 12 X13 Done 1 F,U,D
74 32/M RT 12 X11 Not done 1 D
75 33/M LT 8X9 Not done 1
76 40/M LT 8X 9 Done 1 F,U,D
77 23/F LT 10 X11 Not done 1
78 38/M LT 15 X11 Not done 3 URS&ICL F,U,D
79 35/F LT 17 X12 Not done 1
80 43/M LT 11 X9 Done 2
81 34/M LT 11X9 Done 1 F,U,D
82 37/M LT 8X9 Not done 1
83 28/M LT 12 X11 Done 1
84 37/M LT 10 X11 Not done 1
85 50/F RT 11X10 Not done 1
86 39/M RT 8 X9 Done 1 F,U,D
87 33/F LT 10 X9 Done 3
88 25/M RT 15 X14 Done 1 F,U,D
89 50/F LT 11 X10 Not done 1
90 42/M LT 12 X10 Not done 2
91 39/M RT 8 X9 Done 1 F,U,D,N
92 29/F RT 11 X10 Done 1
93 27/F RT 8 X9 Not done 1
94 24/F RT 8 X9 Done 1
95 45/M RT 15 X10 Not done 2 F,U,D
96 27/M RT 12X9 Done 1 F,U,D
97 33/M RT 8X9 Not done 1
98 38/M RT 17 X13 Done 3 URS&ICL F,U,D
99 25/M RT 15 X9 Not done 2
100 37/F RT 17 X10 Not done 2
101 38/M RT 8 X9 Done 1
102 39 / M LT 12 X10 Done 1 F,U,D
S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
103 52/M RT 14x13 Not done 2
104 34/M LT 11x10 Done 1
105 41/M LT 11x9 Not done 1
106 38/M RT 14x11 Done 2 F,U,D
107 57/M RT 16x15 Done 3 D
108 45/F LT 13x11 Not done 3 URS&ICL
109 30/M LT 12x9 Not done 2
110 39/M LT 12x9 Done 1
111 29/M RT 12x11 Done 1 F,U,D
112 33/M LT 13x11 Done 2
113 40/M LT 11.x10 Not done 1
114 45/M RT 11.x 9 Not done 1
115 36/F RT 9x8 Done 1
116 60/M RT 13x11 Not done 1
117 28/M LT 10x9 Done 1 F,U,D
118 30/M LT 11x9 Not done 1
119 26/M LT 10x9 Done 3
120 40/F LT 9x8 Not done 1 D
121 41/M LT 10x9 Done 1
122 37/F LT 11x10 Not done 1
123 30/M RT 10x11 Done 1 D
124 40/M LT 11x10 Not done 2
125 27/M LT 9x8 Not done 1
126 50/F LT 9x8 Not done 1
127 30/M LT 10x9 Done 1
128 50/M RT 11x10 Not done 1
129 45/M RT 18x12 Not done 2 D,N
130 24/M LT 8x12 Done 1 F,U,D
131 35/M LT 11x10 Not done 1
132 24/F RT 14x11 Done 1 D,N
133 20/M LT 11x10 Not done 1
134 38/F RT 13x11 Not done 3
135 42/F LT 12x10 Not done 1
136 28/F LT 12x11 Not done 1 D
137 55/M LT 11x10 Done 1
138 55/M LT 12x10 Done 1 F,U,D
139 60/F LT 13x12 Done 3 D
140 60/M LT 12x11 Not done 1
141 23/F RT 8x9 Done 1
142 32/M RT 11x10 Not done 1
143 33/M RT 11x10 Not done 1
144 27/M RT 15x13 Done 2 F,U,D
145 30/M LT 13X11 Not done 1
146 23/M RT 8x9 Not done 1
147 27/F LT 10x9 Done 1 D
148 50/M LT 11x10 Not done 2
149 42/M LT 11x10 Done 1 F,U,D
150 26/M LT 10x9 Not done 1
151 33/M LT 12x10 Done 1
152 31/M RT 8x9 Done 1
153 47/M RT 13x11 Not done 1
154 23/M RT 10x9 Done 3
S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
155 30/M LT 11x10 Not done 1
156 40/M RT 11x10 Not done 1
157 39/F LT 14x13 Not done 2 D
158 38/M LT 11x8 Done 1
159 42/F LT 16x13 Not done 3 URS&ICL F,U,D
160 39/M RT 15x11 Not done 1 F,U,D,N
161 30/M RT 12x11 Done 1 D
162 38/M LT 12x11 Done 1
163 49/M LT 12x11 Done 2
164 26/M RT 11x10 Not done 1
165 52/M LT 12x11 Done 1 U,D
166 30/M RT 10x8 Done 1
167 35/M RT 8x7 Not done 2
168 42/M LT 10x.8 Not done 1
169 31/M RT 8x7 Done 1
170 34/M RT 8x7 Not done 1
171 35/M LT 12x11 Done 1
172 36/F LT 18x16 Not done 3 URS&ICL D
173 31/M LT 9x8 Not done 1
174 30/M LT 11x10 Done 2
175 27/M RT 12X11 Done 1 D
176 31/M RT 12x11 Not done 1
177 47/M LT 9x8 Not done 2
178 50/F LT 10x9 Done 1
179 27/M RT 15x13 Done 3 F,U,D
180 39/M LT 16x13 Not done 3
181 46/F RT 14x12 Done 1
182 53/F RT 12x11 Not done 1
183 19/M RT 10x8 Done 3
184 50/M RT 11X10 Not done 1
185 28/M LT 14x12 Done 2 F,U,D,N
186 42/M LT 14x12 Not done 1
187 29/M RT 13x12 Not done 1 F,U,D,N
188 32/M RT 17x12 Done 2 D
189 37/M LT 14x11 Done 2 F,U,D
190 35/F LT 11x8 Not done 1
191 54/M RT 11x10 Done 1 F,U,D
192 27/M LT 13x10 Not done 2
193 40/M LT 11x10 Done 1
194 36/M LT 16x15 Not done 3
195 63/M RT 9x.8 Done 1
196 48/M LT 11x10 Not done 1
197 36/M LT 13X11 Not done 2
198 33/M LT 11x.0 Not done 1
199 22/F LT 10x9 Not done 1
200 37/M LT 12x10 Done 1 F,U,D
201 34/M LT 9x8 Not done 2
202 34/M RT 14x13 Not done 1
203 40/F LT 15x9 Done 2 F,U,D,N
204 60/M LT 9X.8 Not done 1
205 60/M RT 10x9 Not done 1
206 26/M RT 13x.1 Done 1 F,U,D
S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
207 60/M RT 10x8 Not done 1
208 30/F RT 11x12 Not done 2
209 41/M LT 11x10 Not done 1
210 35/F RT 11x1.0 Done 1 F,U,D
211 46/M LT 13x12 Done 1 D
212 28/M LT 9x8 Not done 1
213 46/M LT 14x13 Not done 2
214 39/M LT 12x10 Done 1 F,U,D,N
215 36/F LT 10x8 Not done 1
216 53/M LT 9x8 Not done 1
217 45/M LT 18x15 Done 2 F,U,D
218 69/M LT 18x16 Done 3 URS&ICL F,U,D
219 29/M LT 10x8 Not done 1
220 38/M LT 12x11 Done 2
221 24/M LT 11x10 Not done 1 D
222 40/M RT 10x8 Not done 1
223 25/M LT 9x8 Not done 1
224 27/M RT 10x8 Done 1 F,U,D
225 34/F RT 7x6 Done 1 F,U,D
226 37/M LT 11x10 Not done 1
227 21/M RT 11x10 Not done 1
228 45/M LT 12x11 Not done 1
229 40/M RT 15x11 Done 2 F,U,D,N
230 40/F RT 16x14 Not done 2 F,U,D,N
231 4/M RT 16x13 Done 2
232 28/M LT 13x11 Not done 1 F,U,D
233 28/M LT 13x11 Not done 1
234 40/M RT 15x9 Done 3 URS&ICL F,U,D
235 22/M LT 12x8 Not done 1
236 16/M LT 10x6 Done 1 U,D
237 32/M LT 10x8 Not done 1
238 50/F LT 13x10 Not done 1 F,U,D
239 40/F RT 11x10 Done 1 F,U,D
240 41/M RT 13x12 Not done 1
241 25/M RT 13x11 Done 1
242 67/M LT 11x12 Done 1
243 23/M RT 14x11 Not done 2
244 62/M RT 11x.0 Done 1 F,U,D
245 55/M RT 13x12 Done 1
246 56/M RT 16x15 Not done 3 URS&ICL F,U,D
247 52/F LT 11x10 Not done 1
248 32/M LT 15x14 Done 2 F,U,D
249 29/F RT 13x11 Done 1
250 35/M LT 11x10 Not done 1
251 30/M LT 10x9 Not done 1
252 57/M RT .8x7 Done 1 F,U,D
253 18/M LT 8x7 Done 1 U,D,N
254 26/M LT 15x13 Not done 2 D
255 38/M RT 15x13 Not done 3 URS&ICL
256 25/M RT 9x7 Done 1 F,U,D
257 57/M RT 15x14 Not done 1
258 32/M LT 11x9 Not done 1
S.No Age/Sex Side Size mm Stenting No. of Sittings Sec. Proce LUTS
259 54/F LT 11x10 Done 1
260 25/M RT 12x10 Not done 1
261 37/M RT 14x11 Not done 2
262 32/M RT 14x11 Done 3 URS&ICL F,U,D
263 54/M LT 13x11 Not done 1
264 60/M RT 17x16 Not done 2
265 28/M LT 13x10 Not done 1
266 38/F LT 11x10 Done 1 F,U,D
267 19/M RT 11x10 Not done 1
268 39/M LT 15x14 Not done 3 URS&ICL
269 60/M LT 10X9 Done 1
270 35/M LT 15x13 Not done 2
271 25/M RT 8x7 Not done 1
272 23/M LT 8x6 Done 1 F,U,D
273 32/M LT 9X8 Not done 1
274 31/M LT 16x15 Done 2
275 37/M LT 16x15 Done 1
276 26/M LT 11x10 Not done 1
277 29/M RT 15x14 Done 3 F,U,D,N
278 45/F LT 11x10 Done 1 F,U,D
279 67/M LT 13x12 Done 1 F,U,D
280 28/M RT 11x11 Not done 1
281 50/M RT 17x10 Done 3
282 33/F RT 9x8 Not done 1
283 29/M LT 9x7 Not done 1
284 30/M RT 13x12 Done 1 U,D
285 68/M LT 11x9 Done 1 F,U,D
286 26/M RT 8x7 Done 1
287 25/M RT 11.x12 Not done 1
288 30/M LT 10x9 Done 1
289 39/M LT 11x10 Not done 1
290 25/M RT 16x15 Done 3 U,D,N
291 38/M LT 11x10 Not done 1
292 65/M LT 14x13 Not done 2 F,U,D
293 28/M RT 10x9 Not done 1
294 23/M RT 11x.0 Done 1 F,U,D,N
295 79/M LT 11x10 Done 1
296 36/F RT 11x10 Done 1 F,U,D
297 27/M LT 13x11 Not done 2
298 40M RT 8x9 Done 1 F,U,D
299 47/M RT 10X.9 Not done 1
300 30/M LT 11x10 Not done 1
F -Frequecy, U - Urgency, D - Dysuria, N - Nocturia
H - Haematuria,  F - Fever, S -Stienstrasse, UC - Ureteric Colic
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S
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H
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S
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H
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S
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F
F,S
F
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CHART 2-AGE DISTRIBUTION AMONG NON STENTED GROUP 
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CHART 3 -STONE FREE RATE  ACCORDING TO SIZE AMONG STENTED AND 
NON STENTED
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CHART 4- PERCENTAGE OF COMPLICATIONS AMONG STENTED  AND 
STENTED
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PLAIN X-RAY KUB WITH UPPER 
URETERIC CALCULUS WITHOUT DJ STENT 
 
    
 
 
PLAIN X-RAY KUB WITH UPPER 
URETERIC CALCULUS WITH  DJ STENT 
    
    
CT SCAN WITH UPPER URETERIC CALCULUS 
   
                   
 
FLUROSCOPIC FOCUSING THE UPPER URETERIC CALCULUS 
 
   
 
                                                
 
       
  
      PROFORMA 
  
 
NAME :                                                AGE & SEX  : 
 
MRD NO : 
 
ADDRESS : 
 
 
PHONE NO: 
 
HISTORY 
 
PAIN – SITE , CHARACTER ,DURATION 
 
HEMATURIA / PYURIA / DYSURIA 
 
FEVER / VOMITING 
 
OTHER LUTS 
 
DM/HT/PT/IHD  
 
H/O DRUG INTAKE 
 
PREVIOUS INTERVENTION/ SURGERY 
 
EXAMINATION 
 
ABDOMEN    : 
 
GENITALIA / P.V  : 
 
P.R       : 
 
OTHER SYSTEMS : 
A COMPARATIVE ANALYSIS BETWEEN STENTED AND  
NON-STENTED TECHNIQUES IN EXTRACORPOREAL      
SHOCK WAVE LITHOTRIPSY FOR UPPER URETERAL 
STONES 
INVESTIGATIONS 
 
H.B%    : 
PCV%    : 
TC     : 
DC     : 
ESR     :  
URINE :ALB   : 
               SUG   : 
               DEP   : 
 
URINE C/S    : 
 
BLOOD SUGAR   : 
R.F.T:   Bl.UREA   : 
              Sr.CREATININE :            
              Sr.ELECTROLYTES: 
 
X RAY KUB: RT/LT /SIZE 
               STENTED / NON-STENTED 
 
 
U/S KUB:    HUN / SIZE 
 
 
 
IVU 
 
 
C.T KUB 
 
 
 
 
OTHER INVESTIGATIONS  
 
ESWL - DETAILS 
 
 
 
 
 
 
FOLLOW UP 
 
TWO WEEKS: 
                                  X RAY KUB: 
 
                                  U/S   KUB: 
 
 
FIRST MONTH: 
                                  X RAY KUB: 
 
                                  U/S   KUB: 
 
 
SECOND MONTH: 
                           X RAY KUB: 
 
                                  U/S   KUB: 
 
 
THIRD MONTH: 
 
                          X RAY KUB: 
 
                                 U/S   KUB: 
 
 
RESULT: 
 
 
                 SUCCESSFUL / FAILURE 
 
 
 
 
REMARKS : 
PATIENT CONSENT FORM
Study Details : A comparative Analysis between Stented and Non-
Stented Techniques in Extracorporeal Shock Wave
' Lithotripsy for Upper Ureteral Stones
Study centre : Department of urology, Madras Medical college,
Chennai-600 003.
Patient may check (r) these boxes
I confirm that I have understood the purpose ofprocedure for the above
study. I have the opportunity to ask question and all my questions and doubts
have been answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I
am free to withdraw at any time without giving reason, without my legal
rights being affected.
I understand that sponsor of the clinical study, others working on the
sponsor's behalf, the ethical committee and the regulatory authorities will not
need my permission to look at my health records, both in respect of current
study and any further research that may be conducted in relation to it, even ifI withdraw from the study I agree to this access. Howevsr, I understand that
my identity will not be revealed in any information released to third parties or
published, unless as required under the law. I agree not to restrict the use of
any data or results that arise from this study.
I agree to take part in the above study and to comply with the
instructions given during the study and faithfully cooperate with the study
team and to immediately inform the study staff if) suffer from any
deterioration in my health or well being or any unexpected or unusual
symptoms.
I hereby consent to participate in this study.
I hereby give permission to undergo complete clinical examination and
diagnostic tests including hematological, biochemical, radiological tests.
Signature/ Thumb Impression:
Patient Name and Address: Place Date
E
E
r
[]
Ttl
Signature of Investi gator
Study Investigator's Name: Place Date
"dgl6to otgrq Onsouddtmc gptuti dUt$l" rggrrrr0fi Bufiuggr0dr
ggs{Omsr odrmw P.nor-iBgrfr 86Fmc$dr 3flgasan Ordg$"
egrrnriiSl $larralurb : Sgu$rreg4ganord$s6ocu.Slflol"
6looiryanar roqg $ gzu6eerl gn rfl,
Glcshonar - 600 OO3.
urfurg 6lugruorrfleh 6luu.ri :
udr1gG'lugruorrfletr srai,n :
uri,g 6lugori $lp-* q/1 gflineqrb.
GuGo gidlu8r-$leiren ro(gggtcu 4rl6fl6irr er5leurrrira6h eran&,1g
ei5lsn6auuir-gl. croirglanr-u.r e$Gpodrecroen Goieqrb, g4p$eneur pg$g L__Jailan&srireeioen 6lupo1rb eund.ruuofl&ouur-r-g.
Dr6itr $teirornricrllo peirofl*aneu:negneir urarGosdGpeiir. rpp l- -l
onrycnn$$annGarn cr$p eul-p$glb cr$g er-r- Cldogrrigd p-Luunroal Drr6irr I I
$lei.reunti.rer5l"l EgiB$ o{lod 6lonohenarnd ooirgrb gdls$ 6lonaimGr--oin. I I
6t$g gl,nq crbro$gaon6Go.rn, Ecp eni$p Grog16 eltirq Go$GlanoirqgrbGung6 ESg qgdre.Slar udrgGlugrir rog$grari croirglanr-ur otgpgar
g4flicoooonen unirlupp(g crein gglo$ Gpanoru5leildDa) dr6ur erdt6$ GleneirslGpeix.
6t$g g$rir6rtl6in (pal6 6lanr-&grb poanana)Gurn, grqanorGurn
uruetru@$$66leneh sn ogt&eroniGr-oiir.
EEg 
€$tiJoflffu urirg 6lsneiren guq&6lenehdGpei'r. cran&g 6len@&ouut-r-
etdlo{corrsafleinuq F'-$gil Glenehorguuin ESp $drenor Go$6laneirgd ro(gi$gl6u
efuofl6g e-ainanoqr-oir $qguGuetr croiirgd e-g$lruofl&SlGp6irr. croin e-r-ol gal6
un$iouur-r-nGarn ep)6ogt cr$riunrng orpri,op$pg rorrprr6uT Gpntnegfl
Glpoinur*r-nGarn e-LG6ur 
€t6rrp ro(gpgt6rr g4mflujh-6 OprflefluGuetr cran Lg}l$
g6rfl6ClGp6in.
urirGoSuorfloin ano6lu.rnrjrurb E-,b................ GE6l
er-aor-erSlryo Grans
urirGafuorrfloin G'luuri ro $6 oflarned
4drornenrfloin aoo6lurmfurb......... ...:$r-rb .... GpS
I
eu.r etlprfu uqor6
€turor 5te-^r uufFrb Feoorir-l
T
Tn
ggdrorn enrfloin 6luur i
:844 25363970
1. Prof. S.K. Raian, Mn
2. Prof. J. Mohinasundaram, MD,Ph'D'DNBkn, fi/ladras Medical College, Chennai €
3. Prof. A. Sundaram, MD
Vice PrinciPal, MMC, Chennai'3
4. Prof R. Handhini' MD
Director, lnstitute of Pharmacology, MMG' Ch-B
5. Prof. Pregna B. Dolia , MD
Director,Institute of Biochemi$ry, MMC, Ch€
8. Prof. C. Raiendran, MD
Director, lnstitute of lnternal Medicine, MMC, Ch€
?. Prof. Md. Ali- MD, DlVl
Professor & Head ,,Dept. of MGE, MMC' Ch€
8. Thiru. $. Govindasamy BA'BL
9. Tmt. Arnold $oulina
rNSTI'fUTIONAI E'rHrc$ coelMrTTsE
NAADR.A.S IffiPTCA.I, CCLLTCN. CHENNAI -g
Telephone No: 044?5305301
Fax
CERTIFICATE OF APPROVAL
lo
Dr.T.R. Ghurunaath
PG in MCh UrologY
Madras Medical College, Chennai €
Dear Br. T.r. Ghurunaath :
The lnstitutional Ethics sommittee of Madras Medical Gollege revieu€d and
discussed your afplication for approval of the proiect I proposal lelinieal trail entitled;; n 
"o*p*fotio" 
iriatysis between stented and non- stented Hhniques in
exbacorporeat strock'**u" lithotripsyfor upper ureteral stones 'No. 0510201CI'
The following members of Ethics Gommitteewere present in the meeting held on
22.10.2010 conduc,ted at Madras Medical Gollege, chennai'3.
Chairperson
Deputy Chairman
Member
Member
Member
Member
-- Lawyer
- 
Social $cientist
we approve the Proposal to be condilcted in its presented form'
$d t. Ghairman & Other Members
The lnstitutional Ethics Gommittee expects t? b-* informed about the progress oJ the
study, any $AE *"uting in the 
""uii* o1i the study, any 
changes in the protocol and
pJtiti"T"rr"tion I informed consent and asks to be provided a copy of the final report
Member-*;.fu Gommittee
